Walk to the Hill for Civil Legal Aid 2017
January 27, 2017
Prince Lobel attorneys joined over 650 attorneys and law students at the 18th Annual Walk…
Tom’s biotechnology experience, gained from both an extensive in-house career as the director of intellectual property for a biopharmaceutical company and from private practice, allows him to help his clients with their complex intellectual property issues. He provides strategic advice and practical assistance in all aspects of patent and intellectual property, including trade secret, trademark, and copyright acquisition and protection, as well as portfolio evaluation and management, licensing, and asset monetization. He further provides clients with legal opinions related to validity and enforceability, patentability, freedom to operate, intellectual property portfolio valuations, and pre-transaction due diligence investigations.
Tom’s in-house experience also includes executing worldwide patent procurement strategies to protect business-critical inventions and formulating company-wide intellectual property policies and procedures on both local and international levels. Tom has considerable experience guiding IP-intensive transactions and ventures such as collaborations and joint ventures. He also assists entrepreneurs and venture capital groups in devising strategies to build value in their intellectual property portfolios.
Having been both a provider and consumer of intellectual property-related legal services, he is adept at leveraging his in-house experience to offer clients cost-effective, chief patent counsel-level services and guidance. Tom’s clients include key decision makers in a variety of public and private organizations, including biotech and medical device companies as well as research universities, both in the U.S. and abroad.
Prior to joining Prince Lobel, Tom was the Founder and Principal of BIPLaw LLC, where he served as IP counsel to emerging, small, and mid-sized biotech companies and research universities in the fields of molecular medicine, vaccines, therapeutic proteins and antibodies (including production and delivery techniques), cancer-related therapies and drugs, bioinformatics, medical diagnostics, medical devices, nanotechnologies, and mechanical inventions.